In a tweet, noted short seller Citron Research reiterates its bearish view on Inovio Pharmaceuticals (INO +14.4%), a favorite among Robin Hood traders.
In April, it published a report questioning the veracity of its assertion that its “secret algorithm” enabled it to design a COVID-19 vaccine candidate in three hours, comparing the company to one-time early-stage star Theranos, since imploded after its false technology claims were exposed.
Citron sees the stock returning to $14 (~49% downside risk) in “short order.”
https://seekingalpha.com/news/3586208-citron-tweets-on-animal-spirits-driving-inovio-pharmaceuticals
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.